Impax Laboratories Confirms Patent Challenge Relating to DEXILANT® Delayed-Release Capsules, 30 mg and 60 mg
April 04 2011 - 1:00PM
Business Wire
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms
that it has initiated a challenge of patents listed by Takeda
Pharmaceutical Company, Ltd. in connection with DEXILANT®
(dexlansoprazole) delayed-release capsules, 30 mg and 60 mg.
Impax filed its Abbreviated New Drug Application (ANDA)
containing a paragraph IV certification for a generic version of
DEXILANT® with the U.S. Food & Drug Administration
(FDA). Following receipt of the notice from the FDA that
Impax’s ANDA had been accepted for filing, Impax notified the New
Drug Application holder and patent owner of its paragraph IV
certification.
On April 1, Takeda Pharmaceuticals Co. LTD, Takeda
Pharmaceuticals North America Inc., Takeda Pharmaceuticals LLC and
Takeda Pharmaceuticals America Inc. filed suit for patent
infringement against Impax in Northern District of California. This
action formally initiates the patent challenge process under the
Hatch-Waxman Act. Based on the filing date of the ANDA, the Company
believes that it is the first to file an ANDA with a paragraph IV
certification on the 30 mg capsule, and expects to be entitled to
180 days of market exclusivity.
Once the ANDA is approved by FDA, Global Pharmaceuticals,
Impax’s generic division, will commercialize the products.
DEXILANT® is used to treat gastroesophageal reflux disease
(GERD), a condition in which backward flow of acid from the stomach
causes heartburn and possible injury of the esophagus (the tube
between the throat and stomach). It is used to treat the symptoms
of GERD, allow the esophagus to heal, and prevent further damage to
the esophagus. DEXILANT® is in a class of medications called proton
pump inhibitors. It works by decreasing the amount of acid made in
the stomach. According to Wolters Kluwer Health, U.S. sales of
DEXILANT® delayed-release capsules, 30 mg and 60 mg were
approximately $20 million and $261 million, respectively, for the
current 12 months ending January 2011.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded
products. Impax markets its generic products through its Global
Pharmaceuticals division and markets its branded products through
the Impax Pharmaceuticals division. Additionally, where
strategically appropriate, Impax has developed marketing
partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a
full range of capabilities in its Hayward, Philadelphia and Taiwan
facilities. For more information, please visit the Company's Web
site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs and expectations
of management. Such statements are based on current expectations
and involve a number of known and unknown risks and uncertainties
that could cause the Company’s future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Such risks and uncertainties include, but are not
limited to, the effect of current economic conditions on the
Company’s industry, business, financial position, results of
operations and market value of its common stock, the ability to
maintain an effective system of internal control over financial
reporting, fluctuations in revenues and operating income,
reductions or loss of business with any significant customer, the
impact of competitive pricing and products and regulatory actions
on the Company’s products, the ability to sustain profitability and
positive cash flows, the ability to maintain sufficient capital to
fund operations, any delays or unanticipated expenses in connection
with the operation of the Taiwan facility, the ability to
successfully develop and commercialize pharmaceutical products, the
uncertainty of patent litigation, consumer acceptance and demand
for new pharmaceutical products, the difficulty of predicting Food
and Drug Administration filings and approvals, the inexperience of
the Company in conducting clinical trials and submitting new drug
applications, reliance on key alliance and collaboration
agreements, the availability of raw materials, the ability to
comply with legal and regulatory requirements governing the
healthcare industry, the regulatory environment, exposure to
product liability claims and other risks described in the Company’s
periodic reports filed with the Securities and Exchange Commission.
Forward-looking statements speak only as to the date on which they
are made, and Impax undertakes no obligation to update publicly or
revise any forward-looking statement, regardless of whether new
information becomes available, future developments occur or
otherwise.
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024